Citizens Initiates Coverage On Faeth Therapeutics with Market Outperform Rating, Announces Price Target of $51

Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc.

FTH

0.00

Citizens analyst Silvan Turkcan initiates coverage on Faeth Therapeutics (NASDAQ: FTH) with a Market Outperform rating and announces Price Target of $51.